Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cardiff Oncology, Inc. (CRDF : NSDQ)

• Company Description    Cardiff Oncology Inc. is a clinical-stage biotechnology company. It engages in developing treatment for cancer patients. The company's product pipeline consists of a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin(R) in KRAS-mutated metastatic colorectal cancer; a Phase 2 study of onvansertib in combination with Zytiga(R) in Zytiga-resistant metastatic castration-resistant prostate cancer; and a Phase 2 study of onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia. Cardiff Oncology Inc., formerly known as Trovagene Inc., is based in SAN DIEGO. Number of Employees: 23

• Price / Volume Information    Yesterday's Closing Price: $1.28 Daily Weekly Monthly 20 Day Moving Average: 759,924 shares Shares Outstanding: 43.31 (millions) Market Capitalization: $55.43 (millions) Beta: 2.04 52 Week High: $8.58 52 Week Low: $1.13 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -14.67% -3.88% 12 Week -52.06% -47.29% Year To Date -78.70% -73.98%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 11055 FLINTKOTE AVENUE - SAN DIEGO,CA 92121 USA ph: 858-952-7570 fax: - ir@cardiffoncology.com https://cardiffoncology.com

• General Corporate Information    Officers Mark Erlander - Chief Executive Officer Rodney S. Markin - Chairman James Levine - Chief Financial Officer James O. Armitage - Director John Brancaccio - Director Peer Information Cardiff Oncology, Inc. (CORR.) Cardiff Oncology, Inc. (RSPI) Cardiff Oncology, Inc. (CGXP) Cardiff Oncology, Inc. (BGEN) Cardiff Oncology, Inc. (GTBP) Cardiff Oncology, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 14147L108 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/04/22 Share - Related Items Shares Outstanding: 43.31 Most Recent Split Date: 2.00 (0.17:1) Beta: 2.04 Market Capitalization: $55.43 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.25 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.05 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.43 Price/Cash Flow: - Price / Sales: 153.55 EPS Growth vs. Year Ago Period: -78.57% vs. Previous Quarter: -8.70% Sales Growth vs. Year Ago Period: 2.78% vs. Previous Quarter: -44.36% ROE 03/31/22 - -25.12 12/31/21 - -21.05 09/30/21 - -19.37 ROA 03/31/22 - -23.77 12/31/21 - -20.06 09/30/21 - -18.53 Current Ratio 03/31/22 - 20.38 12/31/21 - 22.28 09/30/21 - 27.32 Quick Ratio 03/31/22 - 20.38 12/31/21 - 22.28 09/30/21 - 27.32 Operating Margin 03/31/22 - -9,447.37 12/31/21 - -7,880.50 09/30/21 - -7,375.65 Net Margin 03/31/22 - -9,447.37 12/31/21 - -7,880.50 09/30/21 - -7,375.65 Pre-Tax Margin 03/31/22 - -9,447.37 12/31/21 - -7,880.50 09/30/21 - -7,375.65 Book Value 03/31/22 - 3.00 12/31/21 - 3.55 09/30/21 - 3.38 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©